Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seoul National University Hospital
With
Consortium for Improving Survival of Lymphoma
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed mantle cell lymphoma
Relapse or progression after 1-3 lines of previous chemotherapy with or without immunologic agents
ECOG performance status 2 or less
Adequate hematologic, hepatic, and renal function i. White blood cells ≥ 3,000 /ul ii. Absolute neutrophil count ≥ 1,000 /ul iii. Platelets ≥ 50,000 /ul iv. Hemoglobin ≥ 9.0 g/dL v. Total bilirubin \< 2 times upper limit of normal vi. AST, ALT \< 2.5 times upper limit of normal vii. Serum creatinine \< 1.5 times upper limit of normal
You may not be if
Previously treated with 4 or more lines of chemotherapy with or without immunologic agents
Previously treated with bortezomib
Treated with a cytarabine-containing regimen as the last line and within 6 months before registration
Other cancer diagnosed within 5 years before registration
Uncontrolled symptomatic CNS involvement of mantle cell lymphoma
Uncontrolled systemic infection
Inherited immunodeficiency disease or AIDS
Pregnancy
Breast-feeding
Peripheral neuropathy of grade 3 or higher
Other health conditions considered to be inappropriate for this trial in the primary physician's opinion
Clareo Health | Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
